Moreover, in the CANTOS trial [73], a double-blind, randomized, placebo-controlled trial that included 10,061 patients with myocardial infarction and inflammatory atherosclerosis denoted by high-sensitivity C-reactive protein (hsCRP) levels ≥2 mg/L, Canakinumab (a monoclonal antibody against IL-1β) showed a significant dose-dependent reduction in HF hospitalization and mortality in the HF subgroup when compared to a placebo. This evidence concerns the gene IL1B and hydrops fetalis.